mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer

被引：0
|
作者：
Musa, F. [1 ]
Alard, A. [2 ]
Blank, S. [1 ]
Pothuri, B. [1 ]
Curtin, J. [1 ]
Schneider, R. [1 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] NYU, Sackler Inst Biomed Sci, New York, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2014年 / 134卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2014.04.032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：434 / 435
页数：2
相关论文
共 50 条
  • [31] A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
    Kreuzinger, Caroline
    Geroldinger, Angelika
    Smeets, Dominiek
    Braicu, Elena Ioana
    Sehouli, Jalid
    Koller, Julia
    Wolf, Andrea
    Darb-Esfahani, Silvia
    Joehrens, Korinna
    Vergote, Ignace
    Vanderstichele, Adriaan
    Boeckx, Bram
    Lambrechts, Diether
    Gabra, Hani
    Wisman, G. Bea A.
    Trillsch, Fabian
    Heinze, Georg
    Horvat, Reinhard
    Polterauer, Stephan
    Berns, Els
    Theillet, Charles
    Castillo-Tong, Dan Cacsire
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7621 - 7632
  • [32] Targeting the Microenvironment in High Grade Serous Ovarian Cancer
    Nwani, Nkechiyere G.
    Sima, Livia E.
    Nieves-Neira, Wilberto
    Matei, Daniela
    CANCERS, 2018, 10 (08):
  • [33] Targeting AKT and DNA-PK as a therapeutic strategy in platinum-resistant high-grade serous ovarian cancer
    Rinne, N.
    Curry, E.
    Fotopoulou, C.
    Gabra, H.
    Cunnea, P.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 88 - 89
  • [34] Comorbidity and prognosis in serous and papillary serous ovarian cancer
    Baron, E.
    Munro, E. G.
    Ahmed, J.
    Goodman, A.
    Del Cannen, M. G.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S116 - S117
  • [35] Neurotensin signaling pathway as a potential therapeutic target in high-grade serous ovarian cancer
    Norris, E. J.
    DeStephanis, D.
    Zhang, Q.
    Tait, D. L.
    Ganapathi, R.
    Ganapathi, M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 71 - 71
  • [36] Novel Hypoxia-Associated Markers of Chemoresistance in High Grade Serous Ovarian Cancer
    McEvoy, L.
    O'Toole, S. A.
    Spillane, C. D.
    Stordal, B.
    Gallagher, M.
    Martin, C. M.
    Norris, L.
    Gleeson, N.
    McGoldrick, A.
    Furlong, F.
    McCann, A.
    Sheils, O.
    O'Leary, J. J.
    JOURNAL OF PATHOLOGY, 2015, 237 : S13 - S13
  • [37] TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
    Gonghua Qi
    Hanlin Ma
    Yingwei Li
    Jiali Peng
    Jingying Chen
    Beihua Kong
    Cell Death & Disease, 12
  • [38] Novel therapeutics in low-grade serous ovarian cancer
    Cobb, Lauren
    Gershenson, David
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (03) : 377 - 384
  • [39] TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
    Qi, Gonghua
    Ma, Hanlin
    Li, Yingwei
    Peng, Jiali
    Chen, Jingying
    Kong, Beihua
    CELL DEATH & DISEASE, 2021, 12 (12)
  • [40] Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.
    Ho, Gwo Yaw
    Lieschke, Elizabeth
    Kyran, Elizabeth
    Shield-Artin, Kristy
    Kondrashova, Olga
    Barker, Holly
    Hollian, Robert
    Cazet, Aurelie
    Thuan Phuong
    Swarbrick, Alex
    McNally, Orla
    Bowtell, David
    Wakefield, Matthew
    Scott, Clare L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345